Cabaletta Bio Inc. is a clinical-stage biotechnology company specializing in engineered T cell therapies for B cell–mediated autoimmune diseases. The company focuses on leveraging its proprietary CABA platform, which includes two main approaches: CARTA, or chimeric antigen receptor T cells for autoimmunity, and CAART, or chimeric autoantibody receptor T cells, designed to selectively target disease-causing B cells while preserving normal immune function. Cabaletta Bio’s lead programs are directed at complex autoimmune indications such as dermatomyositis, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, and pemphigus vulgaris, reflecting its emphasis on severe, immune-driven disorders with significant unmet medical need. By applying cell therapy concepts that have been validated in oncology to autoimmune disease, Cabaletta Bio occupies a distinct niche at the intersection of immunology and advanced therapeutics. Founded in 2017 and headquartered in Philadelphia, Pennsylvania, the company operates within the healthcare and biotechnology sectors, serving global clinical and research communities developing next-generation treatments for autoimmune conditions.